Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) involves multiple organ systems, mainly lungs [1]. Secondary bacterial infections are very common in post-viral infections. Community-acquired staphylococcal pneumonia is usually seen in patients recovering from influenza with an ...

  2. 9 Ιαν 2024 · Although most patients hospitalized for COVID-19 pneumonia show gradual functional recovery, a subset of patients have persistent dyspnea and impaired pulmonary function, most notably reduced diffusion capacity, at more than 1 year of follow-up.

  3. Common causes of cavitary lung lesions must be investigated appropriately in all patients. Clinicians must be aware of evolving CT findings of COVID-19 and must arrange appropriate follow-up of convalescent patients with COVID-19 to ensure complete recovery. Learning points.

  4. The lung cavity in a COVID patient is an under-recognized entity. This case report highlights the need for further studies to determine the cause of cavitation, which could be related to COVID infection or its treatment.

  5. 12 Ιαν 2021 · Cavitary lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality. Pulmonary radiological findings of the novel coronavirus disease 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass ...

  6. 1 Ιουν 2023 · The mean cavitary lesion detection time after SARS-CoV-2 PCR positivity was 53.2 days (range = 23-116 days). Six (40%) patients had documented pulmonary embolism during the follow-up period. Galactomannan was positive in two patients.

  7. 30 Αυγ 2022 · Familiarity with the typical long-term sequelae of COVID-19 pneumonia at chest imaging is important in evaluating potential causes of chronic respiratory symptoms in survivors, assessing improvement at follow-up imaging, and distinguishing expected post–COVID-19 findings from other lung conditions.